Gilmore O’Neill, Editas Medicine CEO

Ed­i­tas halts lead CRISPR pro­gram af­ter ef­fi­ca­cy da­ta un­der­whelm

Ed­i­tas Med­i­cine will put a wrap on its lead clin­i­cal pro­gram af­ter re­port­ing dis­ap­point­ing re­sults from a Phase I/II tri­al.

The biotech, one of the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.